Drugs / NCO-48 Fumarate
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04629976 | Jan 2021 → Sep 2022 | chronic hepatitis B virus infection | Nucorion Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NCO-48 Fumarate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04629976 ↗ |
| Route | Oral | “multiple oral dose study” NCT04629976 ↗ |